CIENCIASMEDICASNEWS: National Guideline Clearinghouse | Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

martes, 5 de julio de 2016

National Guideline Clearinghouse | Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

National Institute for Health and Care Excellence (NICE)

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. This updates a previously published guideline summary.

Guideline Title

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. London (UK): National Institute for Health and Care Excellence (NICE); 2016 Feb 24. 22 p. (Technology appraisal guidance; no. 385).

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia. London (UK): National Institute for Health and Clinical Excellence (NICE); 2007 Nov. 30 p. (Technology appraisal guidance; no. 132).

This guideline meets NGC's 2013 (revised) inclusion criteria.